Production (Stage)
Edgewise Therapeutics, Inc.
EWTX
$15.29
-$0.13-0.84%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.20M | 9.17M | 8.21M | 7.43M | 7.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.96M | 45.54M | 40.43M | 38.11M | 34.75M |
| Operating Income | -45.96M | -45.54M | -40.43M | -38.11M | -34.75M |
| Income Before Tax | -40.80M | -39.66M | -34.13M | -31.50M | -28.53M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.80M | -39.66M | -34.13M | -31.50M | -28.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.80M | -39.66M | -34.13M | -31.50M | -28.53M |
| EBIT | -45.96M | -45.54M | -40.43M | -38.11M | -34.75M |
| EBITDA | -45.45M | -44.96M | -39.89M | -37.63M | -34.28M |
| EPS Basic | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 |
| Normalized Basic EPS | -0.27 | -0.26 | -0.23 | -0.21 | -0.20 |
| EPS Diluted | -0.43 | -0.42 | -0.36 | -0.34 | -0.33 |
| Normalized Diluted EPS | -0.27 | -0.26 | -0.23 | -0.21 | -0.20 |
| Average Basic Shares Outstanding | 95.13M | 94.72M | 93.81M | 93.52M | 87.57M |
| Average Diluted Shares Outstanding | 95.13M | 94.72M | 93.81M | 93.52M | 87.57M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |